VERACYTE, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
VERACYTE, INC. (VCYT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $11.20 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-02-26
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-12-31 was $514.00K, a 157.00% increase year-over-year.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-09-30 was $3.00K, a 99.25% decline year-over-year.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-06-30 was $18.00K, a 98.29% decline year-over-year.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2016-03-31 was $365.00K, a 151.72% increase year-over-year.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $11.20M, a 27.74% decline from fiscal 2024.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $15.50M, a 72.22% increase from fiscal 2023.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $9.00M, a 42.86% increase from fiscal 2022.
- VERACYTE, INC. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $6.30M, a 73.75% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|---|---|
| 2025-12-31 | $11.20M 10-K · filed 2026-02-26 | |||||
| 2024-12-31 | $15.50M 10-K · filed 2026-02-26 | |||||
| 2023-12-31 | $9.00M 10-K · filed 2026-02-26 | |||||
| 2022-12-31 | $6.30M 10-K · filed 2025-02-28 | |||||
| 2021-12-31 | $24.00M 10-K · filed 2024-02-29 | |||||
| 2020-12-31 | $32.90M 10-K · filed 2023-03-01 | |||||
| 2019-12-31 | $31.30M 10-K · filed 2022-02-28 | |||||
| 2018-12-31 | $4.90M 10-K · filed 2021-02-22 | |||||
| 2017-12-31 | $700.00K 10-K · filed 2020-02-25 | |||||
| 2016-12-31 | $514.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-25 | $517.00K derived: sum of 2 quarters · filed 2019-02-25 | $535.00K derived: sum of 3 quarters · filed 2019-02-25 | $900.00K 10-K · filed 2019-02-25 | ||
| 2016-09-30 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $21.00K derived: sum of 2 quarters · filed 2016-11-03 | $386.00K 10-Q · filed 2016-11-03 | $586.00K derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $383.00K 10-Q · filed 2016-08-03 | $583.00K derived: sum of 3 quarters · filed 2018-02-27 | $983.00K derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2016-03-31 | $365.00K 10-Q · filed 2016-05-05 | $565.00K derived: sum of 2 quarters · filed 2018-02-27 | $965.00K derived: sum of 3 quarters · filed 2018-02-27 | $2.02M derived: sum of 4 quarters · filed 2018-02-27 | ||
| 2015-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | $600.00K derived: sum of 2 quarters · filed 2018-02-27 | $1.66M derived: sum of 3 quarters · filed 2018-02-27 | $1.80M 10-K · filed 2018-02-27 | ||
| 2015-09-30 | $400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $1.46M derived: sum of 2 quarters · filed 2016-11-03 | $1.60M 10-Q · filed 2016-11-03 | $1.80M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-06-30 | $1.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | $1.20M 10-Q · filed 2016-08-03 | $1.40M derived: sum of 3 quarters · filed 2017-03-01 | $1.60M derived: sum of 4 quarters · filed 2017-03-01 | ||
| 2015-03-31 | $145.00K 10-Q · filed 2016-05-05 | $100.00K 10-Q · filed 2015-05-15 | $345.00K derived: sum of 2 quarters · filed 2017-03-01 | $545.00K derived: sum of 3 quarters · filed 2017-03-01 | $3.25M derived: sum of 4 quarters · filed 2017-03-01 | |
| 2014-12-31 | $200.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $400.00K derived: sum of 2 quarters · filed 2017-03-01 | $3.10M derived: sum of 3 quarters · filed 2017-03-01 | $3.20M 10-K · filed 2017-03-01 | ||
| 2014-09-30 | $200.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05 | $2.90M derived: sum of 2 quarters · filed 2015-11-05 | $3.00M 10-Q · filed 2015-11-05 | $4.40M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-06-30 | $2.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $2.80M 10-Q · filed 2015-08-13 | $4.20M derived: sum of 3 quarters · filed 2016-03-14 | $6.00M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-03-31 | $100.00K 10-Q · filed 2015-05-15 | $1.50M derived: sum of 2 quarters · filed 2016-03-14 | $3.30M derived: sum of 3 quarters · filed 2016-03-14 | $4.50M derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2013-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $3.20M derived: sum of 2 quarters · filed 2016-03-14 | $4.40M derived: sum of 3 quarters · filed 2016-03-14 | $4.90M 10-K · filed 2016-03-14 | ||
| 2013-09-30 | $1.80M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $3.00M derived: sum of 2 quarters · filed 2014-11-13 | $3.50M 10-Q · filed 2014-11-13 | $3.46M 10-Q · filed 2013-11-25 | $3.59M derived: sum of 4 quarters · filed 2015-03-25 | |
| 2013-06-30 | $1.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-14 | $1.70M 10-Q · filed 2014-08-14 | $1.79M derived: sum of 3 quarters · filed 2015-03-25 | |||
| 2013-03-31 | $500.00K 10-Q · filed 2014-05-09 | $588.00K derived: sum of 2 quarters · filed 2015-03-25 | ||||
| 2012-12-31 | $88.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-25 | $200.00K 10-K · filed 2015-03-25 | ||||
| 2012-09-30 | $112.00K 10-Q · filed 2013-11-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |